Key result
L-carnitine treatment in patients with chronic heart failure significantly improved overall efficacy (OR 3.47, P<0.01) and left ventricular ejection fraction (WMD 4.14%, P=0.01).
Why the study?
Does L-carnitine treatment improve clinical outcomes and cardiac function in patients with chronic heart failure?
Population
17 RCTs pooling 1625 patients with chronic heart failure (CHF)
Comparison
L-carnitine (L-C) treatment vs Control group
Design
Meta-analysis
Authors
Loading...
L-carnitine may support adjunctive use in chronic HF for efficacy and LVEF gains; extends meta-analytic evidence but requires outcome-focused RCTs.
Meta-Analysis (n=1,625)
Does L-carnitine treatment improve clinical outcomes and cardiac function in patients with chronic heart failure?
Odds Ratio: 3.47
p-value: p=<0.01
L-carnitine treatment improves clinical symptoms, cardiac function, and biomarker levels in patients with chronic heart failure, with good tolerance.
Song et al. (2017) conducted a meta-analysis in chronic heart failure (n=1,625). L-carnitine vs. control was evaluated on overall efficacy (OR 3.47, p=<0.01). L-carnitine treatment in patients with chronic heart failure significantly improved overall efficacy (OR 3.47, P<0.01) and left ventricular ejection fraction (WMD 4.14%, P=0.01).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: